JUL 22, 2015 11:32 AM PDT

Molecule Makes Ovarian Cancer Deadly

WRITTEN BY: Ilene Schneider
Ovarian cancer strikes terror in women, because symptoms may not be apparent until it is too late for appropriate treatment. There are few reliable early detection tests and few treatment options.
Canadian researchers target LKB1 molecule as problem, rather than solution, to ovarian cancer.
According to the Centers for Disease Control, all women are at risk for ovarian cancer, but older women are more likely to get it. Approximately 90 percent of women who get ovarian cancer are older than 40, and the greatest number are 60 or older. Annually, about 20,000 women in the United States get ovarian cancer. It is the eighth most common cancer and the fifth leading cause of cancer death in American women (http://www.cdc.gov/cancer/ovarian/pdf/ovarian_facts.pdf)

Researchers at Lawson Health Research Institute in London, Ontario,
Canada have discovered a new target for ovarian cancer therapy. Contradicting other research, the Lawson study discovered that LKB1, a molecule that regulates the metabolism of many adult cells, makes the cancer cells lethal and resistant to chemotherapy. Lawson's Dr. Trevor Shepherd, who is solely dedicated to finding a cure for ovarian cancer, grows cancer cells in 3D structures, called "spheroids," to understand how they grow in patients. The sticky spheroids can attach themselves to different organs, but in the laboratory "they can sit dormant and unnoticed for months or years before growing and becoming resistant to chemotherapy," the article ."Intact LKB1 activity is required for survival of dormant cancer spheroids," Oncotarget, July 2015, explains (http://www.sciencedaily.com/releases/2015/07/150722101841.htm).

Dr. Shepherd's laboratory recently found that the spheroids activate a "stress signal." The key molecule that controls the signal is called LKB1, a primary upstream kinase of adenine monophosphate-activated protein kinase (AMPK), a necessary element in cell metabolism.

Acccording to Dr. Shepherd, "Previous studies stated that LKB1 was a tumor suppressor in ovarian cancer, meaning that tumor cells need to get rid of LKB1 to cause cancer, but our work is in direct conflict with these studies. We definitively show that ovarian cancer cells still have LKB1 and that this molecule allows ovarian cancer spheroids to change their metabolism, promote tumor cell survival and make them more resistant to chemotherapy."

By rebutting the other studies, Dr. Shepherd has discovered a target that has potential for new therapy options. As he says, "There are currently no therapies or drugs that target LKB1. Based on these findings, our lab is exploring several different strategies to understand and target LKB1 and its related molecules in ovarian cancer spheroids and developing the essential pre-clinical models to see if this can be translated to ovarian cancer patients."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUN 08, 2021
Immunology
Fueling the Immune System's Killers
JUN 08, 2021
Fueling the Immune System's Killers
There’s a group of “killers” protecting your body against infections and eliminating potentially cance ...
JUN 18, 2021
Cancer
Cancer cell lines are too dissimilar from human cancer cells
JUN 18, 2021
Cancer cell lines are too dissimilar from human cancer cells
A new study finds cultured cancer cells lack genetic similarity to humans. This is concerning because cancer cell lines ...
JUN 26, 2021
Cancer
Immunotherapy Drug Shows Promise for Obese Patients with Breast Cancer
JUN 26, 2021
Immunotherapy Drug Shows Promise for Obese Patients with Breast Cancer
Research shows that obese patients with cancers including ovarian and melanoma may respond better to a certain kind of i ...
AUG 19, 2021
Immunology
Immune Enzyme Kills Viruses but Makes Tumors Stronger
AUG 19, 2021
Immune Enzyme Kills Viruses but Makes Tumors Stronger
Robert Louis Stevenson’s 1886 novel Strange Case of Dr. Jekyll and Mr. Hyde describes a man who is a kind, respect ...
AUG 25, 2021
Cell & Molecular Biology
Sino Biological's Listing on the Shenzhen Stock Exchange
AUG 25, 2021
Sino Biological's Listing on the Shenzhen Stock Exchange
China, August 16, 2021 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biot ...
SEP 22, 2021
Cancer
Whole Genome Sequencing for Cancer Diagnostics
SEP 22, 2021
Whole Genome Sequencing for Cancer Diagnostics
The human genome consists of genetic material known as DNA.  We all have unique DNA sequences made up of four bases ...
Loading Comments...